http://www.iltoopharma.com/ 2023-05-09T16:58+01:00 1.0 http://www.iltoopharma.com/legal-mentions/ 2025-08-05T18:25+01:00 0.9 http://www.iltoopharma.com/clinical-development/ 2017-03-24T18:25+00:00 0.9 http://www.iltoopharma.com/contact/ 2017-03-29T20:21+01:00 0.9 http://www.iltoopharma.com/science/ 2022-11-09T10:50+00:00 0.9 http://www.iltoopharma.com/news/ 2021-06-01T17:17+01:00 0.9 http://www.iltoopharma.com/about-us/scientific-advisory-board/ 2021-06-01T16:21+01:00 0.9 http://www.iltoopharma.com/about-us/partnership/ 2021-06-01T16:30+01:00 0.9 http://www.iltoopharma.com/clinical-development/autoimmune-and-inflammatory-diseases/ 2021-07-15T14:47+01:00 0.9 http://www.iltoopharma.com/clinical-development/type-1-diabetes/ 2021-06-03T15:03+01:00 0.9 http://www.iltoopharma.com/clinical-development/pipeline/ 2023-09-05T13:18+01:00 0.9 http://www.iltoopharma.com/about-us/board-of-directors/ 2025-08-27T16:36+01:00 0.9 http://www.iltoopharma.com/clinical-development/amyotrophic-lateral-sclerosis/ 2021-06-03T15:05+01:00 0.9 http://www.iltoopharma.com/clinical-development/systemic-lupus-erythematosus/ 2022-12-01T14:52+00:00 0.9 http://www.iltoopharma.com/managed-access-programs/ 2023-09-05T14:35+01:00 0.9 http://www.iltoopharma.com/2025/05/10/iltoo-pharma-announces-publication-of-the-results-of-a-phase-iib-trial-for-als-using-low-dose-il-2/ 2025-05-09T23:39+01:00 0.9 http://www.iltoopharma.com/2024/09/13/iltoo-pharma-announces-publication-of-bipolar-depression-study-in-a-peer-reviewed-journal/ 2025-05-09T18:18+01:00 0.9 http://www.iltoopharma.com/2024/09/02/iltoo-pharma-to-attend-the-promise-of-interleukin-2-therapy-meeting/ 2024-09-13T15:09+01:00 0.8 http://www.iltoopharma.com/2023/09/14/iltoo-pharma-announces-managed-access-program-for-als-patients/ 2024-09-13T10:33+01:00 0.8 http://www.iltoopharma.com/2023/06/21/iltoo-pharma-joins-the-global-day-of-recognition-of-als-mnd/ 2023-06-21T17:04+01:00 0.7 http://www.iltoopharma.com/2023/05/23/iltoo-pharma-announces-that-ilt-101-has-achieved-orphan-drug-designation/ 2023-05-23T09:51+01:00 0.7 http://www.iltoopharma.com/2023/05/09/iltoo-pharma-and-the-mirocals-consortium-announce-the-signing-of-licence-agreement-for-the-development-of-low-dose-interleukin-2-as-a-potential-treatment-for-amyotrophic-lateral-sclerosis/ 2023-05-09T10:07+01:00 0.6 http://www.iltoopharma.com/2022/12/06/iltoo-pharma-announces-the-results-of-a-phase-iib-trial-for-als-using-low-dose-il-2/ 2022-12-06T16:18+00:00 0.6 http://www.iltoopharma.com/2022/11/21/iltoo-announces-it-will-attend-the-33rd-international-symposium-on-alsmnd/ 2022-12-06T15:40+00:00 0.5 http://www.iltoopharma.com/2022/09/01/iltoo-pharma-to-sponsor-the-symposium-the-promise-of-interleukin-2/ 2022-10-21T10:16+01:00 0.5 http://www.iltoopharma.com/2021/09/17/iltoo-announces-the-appointment-of-jeff-lyons-as-ceo/ 2022-10-24T14:58+01:00 0.4 http://www.iltoopharma.com/2021/07/08/iltoo-announces-jose-achache-appointed-chairman-of-the-board/ 2022-10-24T16:46+01:00 0.4 http://www.iltoopharma.com/2021/06/01/iltoo-pharma-to-attend-the-promise-of-interleukin-2-webinar/ 2021-06-01T17:15+01:00 0.3 http://www.iltoopharma.com/2021/05/20/iltoo-pharma-to-attend-3rd-treg-directed-therapies-summit/ 2021-06-01T17:06+01:00 0.3 http://www.iltoopharma.com/2021/05/03/iltoo-pharma-hires-head-of-clinical-operations/ 2022-10-24T16:48+01:00 0.2 http://www.iltoopharma.com/2018/03/13/iltoo-pharma-to-present-at-treg-summit-2018-in-boston/ 2018-03-14T14:12+00:00 0.2 http://www.iltoopharma.com/2017/04/10/hello-world/ 2022-10-21T10:30+01:00 0.1 http://www.iltoopharma.com/2016/09/27/iltoo-pharma-to-present-at-sachs-forum-basel-switzerland/ 2017-04-26T14:13+01:00 0.0